Conversion From Fast Acting Oral Opioids to Abstral®
Status:
Terminated
Trial end date:
2011-12-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy when using a novel dose
conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl
(Abstral) for treatment of breakthrough cancer pain (BTcP).